Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Nuwellis, Inc. filings on SEC EDGAR ↗
Nuwellis, Inc. filed an updated corporate investor presentation dated November 17, 2026, to be used for upcoming investor communications and conferences. The presentation highlights the company's Aquadex ultrafiltration technology, its $4.4 billion U.S. market opportunity, and year-to-date revenue growth of 13%.
Nuwellis, Inc. reported net sales of $6.58 million for the nine months ended September 30, 2026, a 12.6% increase over the prior year. Despite improved gross margins, the company incurred a net loss of $11.34 million, driven by higher operating expenses and significant financing-related costs, though this was an improvement from the $15.10 million loss in the same period of 2025.
Nuwellis reported Q3 2026 financial results with net sales of $2.2 million and a 24% improvement in operating loss to $2.1 million. The company highlighted significant gross margin expansion to 69.5% and an 88% year-to-date increase in Aquadex console unit sales, which builds the installed base for future recurring revenue.
Term
Q3 2026
“We have made meaningful progress in strengthening Nuwellis both commercially and financially. Year to date, console unit sales have nearly doubled, expanding our installed base and creating a larger opportunity to grow recurring circuit revenue. Although our third quarter faced a tough comparison against the prior-year period when we fulfilled a significant backorder, the underlying momentum in our business remains strong, as evidenced by the growth in our pediatric segment.”
Mike McCormick, Nuwellis President and Chief Executive